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Abstract 
Purpose Some authors observed increased carboplatin-associated myelotoxicity in 
obese patients which was exclusively attributed to elevated AUC. To investigate the potential 
contribution of functional changes of cells primarily responsible for myelopoiesis, 
granulocyte-macrophage progenitors (CFU-GM) were studied in obesity-associated diabetes 
mellitus (DMT2). 
Methods The most frequently used animal model of human obesity with DMT2 is db/db 
mouse. Cellularity, frequency of CFU-GM and total CFU-GM content of femoral bone 
marrow was measured after 100 mg/kg dose of carboplatin in vivo. To exclude influence of 
pharmacokinetic changes direct toxicity of carboplatin on CFU-GM was also determined in 
vitro and was compared with other anticancer agents, namely doxorubicin, 5-fluorouracil and 
4-thiouridylate. 
Results After intraperitoneal administration of carboplatin, each measured 
characteristics of bone marrow function were more significantly suppressed and the induced 
neutropenia were more serious in db/db mice than in the controls. The increased 
myelotoxicity seemed to be a direct effect on myeloid progenitor cells since their increased in 
vitro sensitivity was found in db/db mice. This was not specific for carboplatin, a similar 
double to 5-fold increase in myelotoxicity of each cytotoxic drug with different mechanism of 
action was observed. Four-thiouridylate, a promising antileukemic molecule with good 
therapeutic index, was by far the least toxic for CFU-GM of db/db mice. 
Conclusions A serious disorder of CFU-GM progenitors was suggested in obese mice with 
DMT2, which eventually might lead to more severe myelotoxicity and neutropenia. Weight 
loss and normalization of glucose homeostasis may be important before chemotherapy of 
malignant diseases in obesity with DMT2. 
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Introduction 
 
In recent years obesity has become one of the most threatening public health problems 
worldwide. It definitely plays a role in the pathogenesis of cardiovascular diseases, but it is 
also an important risk factor of many types of malignant tumors, including colon, 
endometrium, breast, kidney, oesophagus, pancreas, gallbladder, liver, and haematological 
malignancies. Additionally, prognosis of malignancies can also be worse in obese than in non-
obese patients [1]. 
The poorer prognosis in obese patients may be due to alterations of several variables 
such as tumour behaviour, immune responses or effects of cytotoxic drugs. Regarding drug 
effects, an inferior treatment outcome might be caused either by a decrease in antitumor 
efficacy or by an increase in toxicity. Fear from increased therapy-related toxicities influences 
chemotherapy dosing, usually by applying various formulas to reduce doses calculated by 
body weights or body surface areas. However, dose reductions may increase the risk of 
relapses and reduce progression-free or overall survival.   
Increased myelosuppression, which is the most frequent dose-limiting toxicity of 
chemotherapy might be explained by increased drug exposure due to changes in 
pharmacokinetics of cytotoxic drugs. Indeed, excess accumulation of adipose tissue in obesity 
may result in substantial variation in pharmacokinetics of some drugs [2]. However, the 
available pharmacokinetic data in obese patients about most anticancer drugs from properly 
powered clinical trials are scarce [3]. This paucity of reliable data, at least in part, ascribed to 
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the fact that drug development and clinical trials in oncology are generally conducted 
irrespective of patients’ body weight, and obesity is a covariate not usually stratified in data 
analysis. Still, it is generally acknowledged that there are considerable alterations in the 
pharmacokinetics of some cytotoxic drugs in obesity, which might even lead to increased 
toxicity but the available data are somewhat contradictory [4-6]. Thompson et al. [7] found no 
differences in pharmacokinetics of daunorubicin between obese and non-obese patients while 
obesity worsen outcome of patients with breast cancer on doxorubicin (chemical structure is 
very close to daunorubicin) + cyclophosphamide therapy [8]. According to the current 
guidelines, overall, there is no rationale to adjust the standard dosing regimens – based on full 
weight – in obese patients [3].   
Carboplatin is used in many solid tumors, among them those, which correlate well 
with obesity, e.g. ovarian or breast cancer. Carboplatin elimination is primarily dependent on 
glomerular filtration rate (GFR), which means that estimation of GFR is essential for optimal 
dose calculation.The most frequently used Calvert formula, which calculates the dose 
necessary for achieving an optimal target AUC, is also based on the accurate estimation of the 
GFR. Several equations have been used to determine the GFR by creatinine clearance. 
However, as these equations are based on estimation serum creatinine level, they tend to 
overestimate creatinine clearance in obese patients [9].  The Cockroft-Gault equation, which 
is the most frequently used to estimate creatinine clearance in Calvert formula, is no 
exception. Thus the overestimation of creatinine clearance may result in overdose and higher 
than expected, extremely high AUC levels in obese patients [4].. To avoid the overdose of 
carboplatin, dose reduction has been suggested by replacing actual body weight with ideal or 
adjusted body weights in these calculations [10].   
Due to dose reductions lower risk of therapy-related toxicities was observed that obese 
patients receive suboptimal doses and anticancer therapy may become insufficient [11]. On 
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contrary even the carboplatin dose was calculated on actual body weight, some authors found 
worse response to carboplatin-paclitaxel chemotherapy in obese and overweight women with 
breast or advanced ovarian cancer [12-13]. On the other hand frequency of serious Grade 4 
neutropenia, as a consequence of myelotoxicity, was higher in obese than in non-obese 
women with lung cancer treated by carboplatin and paclitaxel despite appropriate dose 
reductions [14].This observation raises possibility of increased sensitivity of the myelopoiesis 
in obese patients, as the risk of other serious adverse effects was not increased. 
Indeed, it is also accepted that obesity may have an effect on myelotoxicity of 
anticancer treatment not only through pharmacokinetic but also through pharmacodynamic 
mechanisms [3, 15].  One of the best characterized and most frequent metabolic dysfunction 
in obesity is insulin resistance which is also a characteristic of diabetes mellitus type 2 
(DMT2). In our previous work we found that rosiglitazone, an insulin sensitizer, had 
myeloprotective effect and ameliorated myelotoxicity of 5-fluorouracil in mice [16-18]. This 
suggested that insulin resistance may influence bone marrow functions and may alter therapy-
related toxicity of anticancer drugs. Later, we were the first to observe an increased in vitro 
toxicity of cytotoxic drugs to the granulocyte-macrophage progenitors in Zucker obese rats 
with insulin resistance and also in non-obese but insulin resistant Goto-Kakizaki rats [15]. 
The association of increased in vitro sensitivity of CFU-GMs with obesity and/or insulin 
resistance suggested a direct damage of these progenitor cells in obesity. Only these few data 
can be found in the current scientific literature about changes caused by obesity in target cells 
of bone marrow and their influence on chemotherapy. 
Carboplatin is frequently used in anticancer protocols in ovarian, breast, testicular and 
prostate cancer, which are strongly associated with obesity. The aims of  our current studies 
was to evaluate myelotoxicity of carboplatin in vivo in obesity-associated diabetes, in which 
metabolic and non-metabolic influences may be stronger on bone marrow cells than in insulin 
Page 5 of 33 Cancer Chemotherapy and Pharmacology
6 
 
resistance or diabetes mellitus without obesity and may have the highest importance in 
clinical practice. We focused on the main target, the granulocyte-macrophage progenitors 
(CFU-GM), in obesity-associated diabetes mellitus type 2 (DMT2) to asses, whether their 
functional changes may additionally result in increased myelotoxicity. 
 
 
Methods 
 
Animals 
 
Twelve-week-old male control (C57BLKS/J-mLepdb/+) and db/db (C57BLKS/J-
mLep
db
/mLep
db) mice were purchased from Janvier Labs (Le Genest Saint Isle, France). The 
present experiments conform to the European Community's guiding principles for the care 
and use of laboratory animals. Studies were carried out according to the approval of the 
Hungarian National Ethics Committee for Animal Research (1/2009 DEMAB). 
 
Chemicals 
 
Following drugs were used: carboplatin (Paraplatin, Bristol Myers-Squibb, Sermoneta, Italy), 
doxorubicin (Adriblastina, Pharmacia & Upjohn SPA, Milan, Italy) and 5-fluorouracil 
(Fluorouracil-TEVA, Pharmachemie, Haarlem, Netherlands). Freshly prepared stock solutions 
were the followings: 100 times dilution of the original carboplatin solution with 10 mg/ml 
concentration and 5000 times dilution of the original 5-fluorouracil solution with 50 mg/ml 
concentration. The original doxorubicin powder was also freshly dissolved first in sterile 
distilled water to get solution with 2 mg/ml concentration then was diluted 5000 times. Stock 
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solutions were dissolved in sterile McCoy’s tissue medium. The chromatography-purified 
sodium salt of 4-thiouridylate (designated as UD29), was prepared as we described earlier 
[19].  
 
Study design 
 
At first the body weight, blood glucose and plasma insulin levels were determined in 10 
control and 10 obese db/db mice to check for the development of insulin resistance and 
DMT2. Changes in peripheral blood cell counts and bone marrow cellularity, the total 
nucleated cell number of the femoral bone marrow, were also investigated. Thereafter, the 
myelopoiesis of these two groups were compared by studying the common progenitors of the 
phagocytic cells, the granulocyte-macrophage colony forming units (CFU-GM). Frequency of 
CFU-GM progenitors was estimated in a specific soft gel colony assay and total femoral 
CFU-GM content was calculated from the cellularity and the frequency of CFU-GM 
progenitor cells. 
In the next round of experiments the myelopoiesis was studied after in vivo 
intraperitoneal administration of a single high dose carboplatin (100 mg/kg) in 10 control and 
10 obese db/db mice. Peripheral blood cell counts, femoral cellularity, frequency of CFU-GM 
progenitor cells and total femoral CFU-GM content were determined 48 hours following the 
injection of carboplatin. 
To study the direct effects of cytotoxic drugs on CFU-GM progenitor cells, nucleated 
bone marrow cells collected from control and db/db mice were cultured in vitro in the 
presence of increasing concentrations (0-0.001-10 mg/L) of either carboplatin or doxorubicin 
or 5-fluorouracil. These three anticancer drugs with different mode of actions were selected 
intentionally to check for any potential drug specific effect on the sensitivity of CFU-GM 
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progenitor cells. In addition to these widely used cytotoxic drugs, the in vitro effects of 
increasing concentrations (1-300 µM) of 4-thiouridylate, a chemically modified 
mononucleotide, on CFU-GM progenitor cells were also investigated in the same way. 
 
Measurement of blood glucose and plasma insulin levels  
 
Blood samples were taken from retroorbital plexus of the mice after overnight fasting 
in the morning. Blood glucose concentrations were determined directly from one drop of 
blood samples using AccuCheck (Roche Diagnostics, Mannheim, Germany). For insulin 
determination the blood samples were centrifuged (Centrifuge 5415R; Eppendorf AG, 
Hamburg, Germany) for 2 minutes at 4°C and 10,000g; then, the plasma was aliquoted, 
frozen, and stored at −70°C. After thawing plasma samples were used directly without any 
extraction processes.  Plasma insulin levels were determined by means of a commercially 
available radioimmunoassay kit (RK-400CT, Institute of Isotopes of the Hungarian Academy 
of Sciences, Budapest, Hungary). 
 
 
Bone marrow samples  
 
Bone marrow was obtained from the femurs of the mice after their extermination by cervical 
dislocation. Femurs were removed and the bone marrow cells were aseptically washed out. 
The concentration of nucleated bone marrow cells in this suspension was determined using a 
hemocytometer and the cellularity of the bone marrow was calculated as the product of the 
volume of the suspension and the cell concentration. 
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CFU-GM assay 
 
Special soft-gel cultures were prepared as described earlier [20]. An inoculate of 2x105/ml 
bone marrow cells were plated in petri dishes (Greiner, Nürtingen, Germany) and were grown 
in McCoy's 5A modified medium (Sigma-Aldrich, Budapest, Hungary) supplemented with 
amino acids, Na pyruvate, NaHCO3, antibiotics (streptomycin, penicillin) and 20% foetal 
bovine serum. Conditioned medium of WEHI-3B cells was also added as a source of colony 
stimulating factors. Methylcellulose (Methocel, 3000-5000 centipoises; FLUKA, Buchs, 
Switzerland) at 1.2% was used as the support matrix for semi-solid cultures. Cultures were 
grown in triplicates for 7 days at 37 ºC at 100% relative humidity in an atmosphere containing 
5% CO2. Colonies were counted under stereomicroscope (Olympus, Hamburg, Germany). At 
the end of the incubation period colonies, defined as cell groups consisting of at least 50 cells, 
were counted under a stereomicroscope (Olympus, Hamburg, Germany). 
 
Statistical analysis 
 
Statistical analyses were performed by GraphPad Prism Software (GraphPad Software, Inc. 
La Jolla, CA, USA). Data obtained from individual mice were used for statistical analysis and 
each variable was evaluated by comparing the obese and non-obese groups with Student’s 
unpaired t test. Differences were regarded as statistically significant at p<0.05. 
 
 
Results 
 
Characteristics of the untreated obese db/db mice  
Page 9 of 33 Cancer Chemotherapy and Pharmacology
10 
 
 
The db/db mice exhibit obesity, hyperglycemia, insulin resistance, and other phenotypes, 
which are physiologically relevant to DMT2. Control mice were heterozygous, expressing 
leptin receptors, had normal glucose metabolism and weight. They were used as a non-
diabetic healthy control (Fig. 1a, b).  
Bone marrow function was evaluated by total cellularity, frequency of granulocyte-
macrophage progenitors (CFU-GM) and total CFU-GM content of the femoral bone marrow. 
Total cellularity of femoral bone marrow reflects the intensity of hemopoiesis. No differences 
were demonstrated in total femoral cellularity between control and obese db/db mice (Fig. 
1c). 
Frequency of CFU-GM progenitors was estimated from soft gel cultures. In these 
cultures the descendant cells of the proliferating CFU-GM progenitors remain together and 
form colonies. Numbers of colonies grown from 105 mononuclear bone marrow cells show 
the frequency of progenitors indicating the intensity of granulopoiesis in bone marrow. There 
were no alterations in number of CFU-GM progenitors in db/db mice compared to control 
mice. Colony forming capability of CFU-GM progenitors of obese db/db mice was not 
impaired in the absence of cytotoxic drugs. According to this, hemopoiesis seemed to be 
intact in these obese, diabetic animals (Fig. 1c). 
 
In vivo effect of carboplatin on peripheral blood cell counts and bone marrow function in 
control and obese db/db mice 
 
A single 100 mg/kg dose of carboplatin resulted in serious bone marrow damage. The 
decrease in CFU-GM progenitor cells was evident 48 hours after carboplatin administration 
both in control and db/db obese mice. Carboplatin significantly decreased the cellularity (Fig. 
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2a) and the frequency of CFU-GM progenitors (Fig. 2b) in groups of db/db mice compared to 
non-obese mice. As a consequence the total CFU-GM pool became significantly lower (Fig. 
2c) which means less regenerative capacity to restore bone marrow functions after the 
damage. Carboplatin caused more serious damage in bone marrow function in obese db/db 
mice than in their littermates.  
White blood cell counts were significantly lower in obese db/db mice than in control 
mice 48 hours after a single 100 mg/kg intraperitoneal dose of carboplatin (Fig. 3a). This 
decrease was primarily due to decreased number of circulating neutrophil granulocytes. 
Absolute neutrophil counts dropped into the very low range. In carboplatin-treated control 
mice the absolute neutrophil count was twice as high as in carboplatin-treated db/db mice 
(1.35±0.09 x109/L) while there were not seen a significant decrease in control mice after the 
carboplatin administration on the second day (Fig. 3b). 
 
In vitro sensitivity of granulocyte-macrophage progenitor cells (CFU-GM) of control and 
obese db/db mice to common cytotoxic drugs  
 
To evaluate whether an increased drug exposure resulted in the increased in vivo 
myelotoxicity of carboplatin, we used the same carboplatin concentrations in vitro in cultures 
of CFU-GM cells isolated from healthy non-obese controls and mice with obesity-associated 
diabetes mellitus. In the presence of increasing concentrations of carboplatin a dose dependent 
decrease in CFU-GM numbers were observed in bone marrow cell cultures of both control 
and db/db mice. However, the sensitivity of CFU-GM cells of obese db/db mice was 
increased to carboplatin, dose-response curve of cells from db/db mice was shifted to lower 
concentrations comparing with that of control mice (Fig 4a).  
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To know whether the increased toxicity is specific for carboplatin on the CFU-GM 
progenitor cells of db/db mice, other well-known anticancer drugs were tested. This is shown 
on Figure 4 that colony numbers (representing CFU-GMs) were significantly lower also for 
doxorubicin (Fig. 4b) and 5-fluorouracil (Fig. 4c), respectively - at any concentrations in cell 
cultures of obese db/db mice than in controls. These drugs were similarly more toxic to CFU-
GM progenitors of db/db than control mice. 
 
Toxicity of 4-thiouridylate, an anticancer drug under investigation, on granulocyte-
macrophage progenitor cells (CFU-GM) of control and obese db/db mice 
 
These findings highlighted that to find new anticancer agents with less toxicity 
especially on progenitor cells of mice (perhaps human patients) with obesity-associated 
diabetes mellitus has a great importance. We chose 4-thiouridylate, a chemically modified 
mononucleotide to study its toxicity on CFU-GM progenitor cells of db/db mice. In our 
previous work we found that it had a promising antileukemic effect in vivo on acute lymphoid 
leukemia human cell lines transplantated them into mice with serious combined immune 
deficiency (SCID). Therapeutic index was good based on the 14-fold less toxicity of 4-
thiouridylate on healthy human CFU-GM progenitors than JY leukemic cell line [21]. Four-
thiouridylate, analogously to the previously tested cytotoxic drugs, resulted in a dose-
dependent decrease in CFU-GM colony numbers in bone marrow cell cultures of both control 
and db/db mice and, also correspondingly to the anticancer drugs, the sensitivity of CFU-GM 
cells of obese db/db mice was higher to 4-thiouridylate (Fig. 5). However 4-thiouridylate, an 
anticancer drug under investigation, was by far the least toxic for CFU-GM of db/db mice. In 
addition, the differences were higher in diabetic db/db mice. Doxorubicin was the most, and 
carboplatin was the least toxic to the CFU-GM progenitor cells among the studied common 
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cytotoxic drugs. The fifty percent inhibitory concentration of 4-thiouridylate on CFU-GM 
cells from db/db mice was 25 times higher than carboplatin and 6500 times higher than 
doxorubicin, while in the control mice the same differences were 15 and 4100 times, 
respectively (Table 1). This may be an advantage in therapy of malignant diseases for diabetic 
and obese patients, if 4-thiouridylate proved to be a proper drug for clinical use in the future. 
 
 
Discussion 
 
Although there is no complete agreement about the quantitative changes of multipotent 
progenitor cells in bone marrow of diabetic mice, similarly to our results (Fig 1c) other 
investigators could not observe decreased number of lineage-committed progenitor cells in 
bone marrow of diabetic mice [22] and even expansion of myeloid progenitors was described 
[23]. At the same time several data suggest a negative impact of diabetes on stem cell 
mobilization from bone marrow probably due to alteration of niche function and not to a 
direct damage of progenitor cells [23-24].  
It should be noted that the above mentioned results were described in diabetes mellitus 
type 1 both in mice and patients. However hyperglycaemia is a characteristics of both DM 
type 1 and type 2, insulin resistance and obesity is associated only with DMT2, resulting in 
more complex disturbances in db/db mice. Db/db mouse is an accepted competent model of 
human obesity and obesity-associated diabetes, because of a spontaneous autosomal recessive 
mutation on chromosome 4 that inhibits the expression of leptin receptors. The developing 
leptin resistance causes obesity and DMT2. 
The observed increased myelotoxicity of carboplatin in db/db mice also supports the 
idea that alteration of the function rather than the number of progenitor cells may better reflect 
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the deleterious effects of obesity-associated diabetes (Fig 2, Fig 4). Altered bone marrow 
function in DM is also suggested by the decreased number and function of bone marrow 
derived angiogenic progenitors which thought to contribute to the impaired endothelial 
renewal [25]. Additionally, it has been reported recently that transplantation of bone marrow 
derived mesenchymal stem cells from non-diabetic animals improved delayed wound healing 
in a diabetic rat model [26] which, although only indirectly, also suggests a potential 
dysfunction of bone marrow progenitor cells in DM. A similar observation, showing 
decreased in vitro proliferative capacity and decreased in vivo direct engraftment potential of 
bone marrow-derived mesenchymal stem cells originated from obese and diabetic db/db mice, 
provided a more direct proof that stem cell impairment is a significant complication of DMT2 
in mice [27].  
As db/db mice are both obese and diabetic it is possible that changes in 
pharmacokinetics in obesity may also play a role in the observed increased in vivo 
myelotoxicity of carboplatin, by resulting in higher drug exposure [4]. Total drug exposure is 
primarily, but not only, determined by the dose and dose schedule and it is well known that 
drug exposure is critical in determination of both beneficial and toxic effects of cancer 
chemotherapy. Large studies suggest that the beneficial impact of adjuvant chemotherapy is 
diminished when full doses of therapy are not given [28-31]. Based on these studies, it is 
generally recommended that chemotherapeutical doses should not be reduced below 85% of 
the standard doses over the entire course of the treatment. 
However contradictory data are available regarding the association of increased 
toxicity of chemotherapy in obese or diabetic individuals, some observations reported 
increased therapy-related myelotoxicity in obese patients, e.g. in obese children with acute 
myeloid leukaemia (AML) [32]. Meloni et al. [33] found delayed granulocyte recovery and 
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increased incidence of infections in obese adults with de novo AML receiving high dose 
chemotherapy and autologous stem cell transplantation.  
Although DM seems to be a strong independent factor influencing mortality of 
patients with malignancies [34-35], there are only a few observations about an increased 
myelotoxicity during chemotherapy. Srokowsky et al. [36] demonstrated in elderly breast 
cancer patients that diabetic patients were more likely to experience toxicities of 
chemotherapy than were non-diabetic patients. Diabetic patients were more likely to be 
hospitalized for any cause, for toxicity in general, and for infection or fever, neutropenia and 
anaemia. Majority of these patients received doxorubicin-based chemotherapy schedules. Our 
data might suggest functional damages of bone marrow progenitor cells in diabetic patients as 
we found that CFU-GM progenitors from mice with obesity-associated diabetes were more 
sensitive to doxorubicin (Fig 4b). 
Our previous results were the first observations of increased toxicity of cytotoxic 
agents to granulocyte-macrophage progenitor cells of obese, insulin resistant Zucker rats in 
vitro. We introduced new methods for evaluating pathophysiological processes associated 
with obesity and insulin resistance. Although there was no difference between the obese and 
the lean control animals in number and proliferation of the haemopoietic progenitors in bone 
marrow, in vitro exposure to carboplatin, doxorubicin and 5-fluorouracil showed higher 
sensitivity of CFU-GM progenitors from Zucker obese rats to the toxicity of anticancer drugs 
than in bone marrow cells from control rats. According to our in vitro model the therapy-
related myelotoxicity might be not only due to the different pharmacokinetic parameters or 
changes in drug exposure but also to the dysfunction of haemopoietic progenitor cells [15].  
Our current in vitro results on CFU-GM from db/db mice correspond to our previous 
results and strongly suggest that increased vulnerability of progenitor cells may contribute to 
increased therapy-related myelotoxicity in obesity-associated diabetes (Fig 4). We tested the 
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sensitivity of the CFU-GM progenitor cells to three widely used cytotoxic drugs with different 
mechanism of action. Carboplatin forms reactive molecular species that alkylate nucleophilic 
groups on DNA bases. Doxorubicin intercalates between DNA base pairs, interacts with 
topoisomerase II and generates free radicals. Five-fluorouracil belongs to the antimetabolites. 
A common dose limiting side effect of all of these cytotoxic agents is myelosuppression 
similarly to other antiproliferative treatments,  
Myelosuppression is the most frequent dose-limiting toxicity of chemotherapy during 
the complex anticancer treatment. This is a consequence of the fact that selectivity of most 
common anticancer drugs is due to killing primarily the rapidly dividing cells, meaning that 
high cytotoxic drug concentrations can also damage normal cells with high turnover, 
especially cells in the bone marrow and gastrointestinal tract. Anticancer agents can inhibit 
the proliferation of both stem and progenitor cells in bone marrow, but progenitor cells have 
shorter duplication times than stem cells; therefore, they are more sensitive to 
chemotherapy-induced damage. As a consequence anemia, neutropenia and thrombocytopenia 
are developed. Neutropenia has the highest influence on survival by higher risk for serious 
infections, which are the leading cause of mortality during chemotherapy of cancer patients. A 
single intraperitoneal dose of carboplatin resulted in  serious neutropenia in mice with 
obesity–associated diabetes as early as 2 days after administration while there were no any 
differences in absolute neutrophil counts in control mice (Fig 3). 
According to our results, obesity-associated diabetes has direct significant effect on an 
important target cell population of cytotoxic drugs, namely CFU-GM, the common ancestors 
of granulocytes and macrophages with serious neutropenia. Toxicity of each tested anticancer 
drug with different mode of actions was similarly double to 5 times higher for CFU-GM 
progenitors from mice with obesity-associated diabetes than those of controls (Table 1). There 
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is only one other similar observation, in vitro 5-fluorouracil could damage progenitors of the 
db/db mice more than progenitors of the controls [37]. 
Our previous findings that insulin itself even insulin sensitizing had myeloprotective 
effect and defended CFU-GM progenitor cells against 5-fluorouracil-caused damage [16-18] 
supported that insulin resistance might be an opposite effect. We also demonstrated that CFU-
GM progenitors of Goto-Kakizaki rats had higher sensitivity against carboplatin, and 
doxorubicin and 5-fluorouracil in vitro than CFU-GM cells of non-insulin resistant control 
rats [15]. Goto-Kakizaki rats are non-obese but insulin resistant animals thus our results 
suggest that insulin resistance may involve CFU-GM progenitor cells. Insulin and insulin-like 
growth factor are well-known early-acting growth factors in hemopoiesis, and they even share 
some insulin receptors, which have good affinity to both of them. If insulin resistance 
involves CFU-GM progenitors, both their survival and proliferation are affected and they 
become more sensitive to any agents with apoptotic and antiproliferative mode of actions.  
Insulin resistance, which characterizes both obesity-associated diabetes and obesity 
may alter tumour cells, too. In majority of cases it does not mean that tumour cells themselves 
become insulin resistant. On the contrary, Novosyadlyy et al [38] found highest density of 
insulin receptors on breast tumor cells in insulin resistant but nonobese diabetic animals with 
accelerated tumor progression. Insulin receptors have a great role in autocrine loops of some 
cancer cells with accelerated tumor progression and their increased numbers explain their 
increased sensitivity to hyperinsulinemia associated with diabetes mellitus or insulin 
resistance with or without obesity.  Insulin receptor abundance and its phosphorilation is 
characteristic for breast cancer cells and are positively related to poor survival [39]. Enhanced 
proliferation rate and survival of tumour cells are well-known result of activated signaling 
through Akt pathway which propagates not only the metabolic but also growth factor like 
effects of insulin [40]. De novo activation of the autocrine loop through insulin receptor 
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signalling, also represent a mechanism of resistance to any antiproliferative or apoptosis 
inducer anticancer drugs.  
On the other hand high insulin receptor density does not accelerate tumour growth if 
there is lack of phosphorilation, if e.g. breast cancer cells express high levels of 
ectonucleotide pyrophosphatase/phosphodiesterase which lead to insulin resistance of tumour 
cells [40]. Therapy resistance may develop against the new insulin receptor tyrosine kinase 
inhibitors such as linsitinib.  
Summarizing the above mentioned data, in obesity-associated diabetes therapeutic 
window of anticancer treatment might be narrower not only because of the higher 
myelotoxicity but also the higher resistance of tumor cells. This highlighted importance of 
new anticancer agents with less toxicity especially to progenitor cells of diabetic patients. As 
a first step we tested toxicity of 4-thiouridylate, an anticancer drug under investigation, on 
granulocyte-macrophage progenitor cells (CFU-GM) of control and obese db/db mice (Fig 5). 
A mononucleotide, 4-thiouridylate showed anti-proliferative activity on various leukemic and 
solid tumour cell lines [19, 41]. Since 4-thiouridylate, as a nucleotide, cannot penetrate into 
the cells, it must exert its activity at the cell surface. The enol-form of the compound carries a 
reactive –SH group which might interact with the cysteinyl side chains of proteins affecting 
their biological function including receptors, involved in the regulation of cell cycle or cell 
death [41]. The pattern of DNA degradation and the elevated caspase-9 activity with 
characteristic changes in the morphology of treated cells strongly suggested that 4-
thiouridylate induces apoptosis. Four-thiourydilate was by far the least toxic for CFU-GM of 
db/db mice, in addition differences were higher for CFU-GM progenitors of mice with 
obesity-associated diabetes than those of control animals (Table 1). Lower toxicity may be 
based on its mode of action, as 5-thiouridylate does not penetrate cell membrane and cause 
direct damage in DNA, it results in probably a receptor-activated apoptosis. 
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According to our current observations, proliferation and survival of CFU-GM 
progenitors were also affected in db/db mice but this could be detected only through their 
higher vulnerability to cytotoxic drugs. The most significant aspect of our new results is to 
emphasize dysfunction of haemopoietic progenitor cells in obesity-associated diabetes. This 
dysfunction could not be detected under physiologic circumstances. However, the 
vulnerability of CFU-GMs to cytotoxic drugs was increased both in vivo and in vitro. While 
the increased in vivo vulnerability might be due to not only direct effects of drugs on 
progenitor cells but also to variations in drug exposure (resulting from pharmacokinetic 
differences) or to effects on other cells in the bone marrow, the increased in vitro vulnerability 
directly demonstrates the damage of progenitor cells. The early occurrence of severe 
neutropenia – as early as 48 hours after administration of carboplatin – also suggests direct 
damage to not only progenitor cells but also circulating mature cells (Fig 3). Disorders in cell 
metabolism and receptorial functions may be responsible for the increased vulnerability of 
progenitor cells which is possibly aggravated by modified cross-talk among bone marrow 
cells and the dysfunctional bone marrow stroma. 
In clinical practice early and low absolute neutrophil count is the most important sign 
of serious myelotoxicity and this immunosuppressed period might lead to development of 
life-threatening infections with high mortality. The longer duration of regeneration may result 
in delay of the next chemotherapy course leading to reduced antitumor efficacy and survival. 
Our results warn that weight loss and normalization of glucose homeostasis may be important 
before cytotoxic chemotherapy in patients with obesity-associated diabetes and might 
improve the outcome of chemotherapy of malignant diseases. 
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Legends to Figures and Table 
 
Figure 1 Characteristics of obese db/db mice in comparison with db/- control mice. 
Body weight (a), blood glucose and plasma insulin level (b), total cellularity of bone marrow 
and frequency of granulocyte-macrophage progenitor cells (CFU-GM) (c) in twelve-week-old 
control, and obese, diabetic db/db mice. (n=10 in each group, values are means ± S.E.M., 
***P<0.001 compared with control, non-obese, non-diabetic mice). 
Figure 2 Effect of in vivo administration of carboplatin on cellularity (a), CFU-GM 
colony numbers (b) and total CFU-GM content (c) of femoral bone marrow in control and 
obese, diabetic db/db mice after 48 hours of a single 100 mg/kg dose. (n=10 in each group, 
values are means ± S.E.M., *P<0.05, ***P<0.001 compared with control mice). 
Figure 3 White blood cell (a) and absolute neutrophil (b) counts in vehicle-treated 
control mice and after 48 hours of a single 100 mg/kg dose of carboplatin (CP) in 12-week-
old control, and obese, diabetic db/db mice. (n=10 in each group, values are means ± S.E.M., 
**P<0.01 and ***P<0.001 compared with carboplatin treated control mice). 
Figure 4 Effect of carboplatin (a), doxorubicin (b) and 5-fluorouracil (c) on CFU-GM 
colony numbers in control and obese, diabetic db/db mice in special soft-gel cultures. Cultures 
were grown in the presence of increasing concentrations of carboplatin, doxorubicin and 5-
fluorouracil. (n=10 in each group, values are means ± SEM, **P<0.01, ***P<0.001 compared 
with control mice).  
Figure 5. Effect of 4-thiouridylate on CFU-GM colony numbers in control and obese, 
diabetic db/db mice in special soft-gel cultures. Cultures were grown in the presence of 
increasing concentrations of 4-thiouridylate (n=10 in each group, values are means ± SEM, 
*P<0.05, **P<0.01, compared with control mice).  
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Table 1. Fifty percent inhibitory concentrations (IC50) of carboplatin, doxorubicin, 5-
fluorouracil and 4-thiouridylate on CFU-GM cells from control db/- and obese, db/db mice.  
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